drugset / Trial / NCT00115115

Summary

Donor pre-treatment with dopamine reduces injury to the kidney graft with consequences on the clinical performance immediately after transplantation: Donor dopamine reduces the requirement of dialysis post transplant, and results in renal function improvements. The purpose of the study is to investigate the potentially therapeutic impact of donor preconditioning with low dose dopamine in human renal transplant recipients from a brain dead donor.

Timeline

Start
2004-03
Primary completion
2007-12
Completion
2009-03

Outcome

Met primary endpoint

paper Fewer recipients in the treatment group needed multiple dialyses (56/227; 24.7%; 95% CI, 19.0%-30.3%; vs 92/260; 35.4%; 95% CI, 29.5%-41.2%; P = .01). PMID 19738091 ↗

paper CONCLUSION: Donor pretreatment with low-dose dopamine reduces the need for dialysis after kidney transplantation. PMID 19738091 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dopamine Small molecule 4 ug/kg —